NASDAQ:ALRN - Aileron Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.50
  • Forecasted Upside: 212.50 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.12
▼ -0.05 (-4.27%)
1 month | 3 months | 12 months
Get New Aileron Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALRN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.50
▲ +212.50% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aileron Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 212.50% upside from the last price of $1.12.
Buy
The current consensus among 3 investment analysts is to buy stock in Aileron Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2021HC WainwrightReiterated RatingBuy$2.00Low
i
11/16/2020Canaccord GenuityReiterated RatingBuy$5.00Medium
i
8/10/2020William BlairReiterated RatingBuyHigh
i
8/4/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Edward White at HC Wainwright
6/29/2020HC WainwrightReiterated RatingBuy$2.00High
i
Rating by Edward White at HC Wainwright
6/5/2020HC WainwrightLower Price TargetBuy$3.00 ➝ $2.00Medium
i
Rating by Edward White at HC Wainwright
6/2/2020Canaccord GenuityReiterated RatingBuyHigh
i
5/12/2020Canaccord GenuityReiterated RatingBuy$5.00High
i
5/11/2020HC WainwrightReiterated RatingBuy$3.00High
i
Rating by E. White at HC Wainwright
4/27/2020HC WainwrightReiterated RatingBuy$3.00High
i
Rating by E. White at HC Wainwright
4/24/2020William BlairReiterated RatingBuyLow
i
3/31/2020HC WainwrightLower Price TargetBuy$6.00 ➝ $3.00High
i
Rating by E. White at HC Wainwright
9/30/2019HC WainwrightReiterated RatingBuy$6.00High
i
9/11/2019HC WainwrightReiterated RatingBuy$6.00High
i
Rating by E. White at HC Wainwright
8/7/2019HC WainwrightReiterated RatingBuy$6.00Medium
i
Rating by E. White at HC Wainwright
5/6/2019William BlairReiterated RatingOutperformHigh
i
Rating by M. Phipps at William Blair
4/9/2019Canaccord GenuityLower Price TargetPositive ➝ Buy$5.00High
i
3/11/2019HC WainwrightInitiated CoverageBuy$7.00High
i
Rating by E. White at HC Wainwright
8/11/2017Canaccord GenuityReiterated RatingBuy$19.00Low
i
7/24/2017William BlairInitiated CoverageOutperform ➝ OutperformHigh
i
Rating by Y. Xu at William Blair
7/24/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$19.00High
i
7/24/2017Canaccord GenuityInitiated CoverageBuy$19.00High
i
7/24/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$20.00High
i
(Data available from 4/21/2016 forward)
Aileron Therapeutics logo
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.
Read More

Today's Range

Now: $1.12
$1.10
$1.17

50 Day Range

MA: $1.45
$1.17
$1.76

52 Week Range

Now: $1.12
$0.46
$2.47

Volume

983,634 shs

Average Volume

3,806,184 shs

Market Capitalization

$101.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Aileron Therapeutics?

The following Wall Street analysts have issued research reports on Aileron Therapeutics in the last twelve months: Canaccord Genuity, HC Wainwright, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ALRN.

What is the current price target for Aileron Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Aileron Therapeutics in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 212.5%. Canaccord Genuity has the highest price target set, predicting ALRN will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Aileron Therapeutics in the next year.
View the latest price targets for ALRN.

What is the current consensus analyst rating for Aileron Therapeutics?

Aileron Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALRN will outperform the market and that investors should add to their positions of Aileron Therapeutics.
View the latest ratings for ALRN.

What other companies compete with Aileron Therapeutics?

How do I contact Aileron Therapeutics' investor relations team?

Aileron Therapeutics' physical mailing address is 490 Arsenal Way, Watertown MA, 02472. The company's listed phone number is 617-995-0900 and its investor relations email address is [email protected] The official website for Aileron Therapeutics is www.aileronrx.com.